Literature DB >> 19282453

A large-scale chemical modification screen identifies design rules to generate siRNAs with high activity, high stability and low toxicity.

Jesper B Bramsen1, Maria B Laursen, Anne F Nielsen, Thomas B Hansen, Claus Bus, Niels Langkjaer, B Ravindra Babu, Torben Højland, Mikhail Abramov, Arthur Van Aerschot, Dalibor Odadzic, Romualdas Smicius, Jens Haas, Cordula Andree, Jharna Barman, Malgorzata Wenska, Puneet Srivastava, Chuanzheng Zhou, Dmytro Honcharenko, Simone Hess, Elke Müller, Georgii V Bobkov, Sergey N Mikhailov, Eugenio Fava, Thomas F Meyer, Jyoti Chattopadhyaya, Marino Zerial, Joachim W Engels, Piet Herdewijn, Jesper Wengel, Jørgen Kjems.   

Abstract

The use of chemically synthesized short interfering RNAs (siRNAs) is currently the method of choice to manipulate gene expression in mammalian cell culture, yet improvements of siRNA design is expectably required for successful application in vivo. Several studies have aimed at improving siRNA performance through the introduction of chemical modifications but a direct comparison of these results is difficult. We have directly compared the effect of 21 types of chemical modifications on siRNA activity and toxicity in a total of 2160 siRNA duplexes. We demonstrate that siRNA activity is primarily enhanced by favouring the incorporation of the intended antisense strand during RNA-induced silencing complex (RISC) loading by modulation of siRNA thermodynamic asymmetry and engineering of siRNA 3'-overhangs. Collectively, our results provide unique insights into the tolerance for chemical modifications and provide a simple guide to successful chemical modification of siRNAs with improved activity, stability and low toxicity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19282453      PMCID: PMC2685080          DOI: 10.1093/nar/gkp106

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  48 in total

1.  RNA interference in mammalian cells by chemically-modified RNA.

Authors:  Dwaine A Braasch; Susan Jensen; Yinghui Liu; Kiran Kaur; Khalil Arar; Michael A White; David R Corey
Journal:  Biochemistry       Date:  2003-07-08       Impact factor: 3.162

2.  Functionalized LNA (locked nucleic acid): high-affinity hybridization of oligonucleotides containing N-acylated and N-alkylated 2'-amino-LNA monomers.

Authors:  Mads D Sørensen; Michael Petersen; Jesper Wengel
Journal:  Chem Commun (Camb)       Date:  2003-09-07       Impact factor: 6.222

3.  Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7.

Authors:  Veit Hornung; Margit Guenthner-Biller; Carole Bourquin; Andrea Ablasser; Martin Schlee; Satoshi Uematsu; Anne Noronha; Muthiah Manoharan; Shizuo Akira; Antonin de Fougerolles; Stefan Endres; Gunther Hartmann
Journal:  Nat Med       Date:  2005-02-20       Impact factor: 53.440

4.  Cleavage of the siRNA passenger strand during RISC assembly in human cells.

Authors:  Philipp J F Leuschner; Stefan L Ameres; Stephanie Kueng; Javier Martinez
Journal:  EMBO Rep       Date:  2006-01-20       Impact factor: 8.807

5.  Fully 2'-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA.

Authors:  Charles R Allerson; Namir Sioufi; Russell Jarres; Thazha P Prakash; Nishant Naik; Andres Berdeja; Lisa Wanders; Richard H Griffey; Eric E Swayze; Balkrishen Bhat
Journal:  J Med Chem       Date:  2005-02-24       Impact factor: 7.446

6.  Argonaute2 cleaves the anti-guide strand of siRNA during RISC activation.

Authors:  Tim A Rand; Sean Petersen; Fenghe Du; Xiaodong Wang
Journal:  Cell       Date:  2005-11-03       Impact factor: 41.582

7.  Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras.

Authors:  James O McNamara; Eran R Andrechek; Yong Wang; Kristi D Viles; Rachel E Rempel; Eli Gilboa; Bruce A Sullenger; Paloma H Giangrande
Journal:  Nat Biotechnol       Date:  2006-06-25       Impact factor: 54.908

8.  Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs.

Authors:  Jürgen Soutschek; Akin Akinc; Birgit Bramlage; Klaus Charisse; Rainer Constien; Mary Donoghue; Sayda Elbashir; Anke Geick; Philipp Hadwiger; Jens Harborth; Matthias John; Venkitasamy Kesavan; Gary Lavine; Rajendra K Pandey; Timothy Racie; Kallanthottathil G Rajeev; Ingo Röhl; Ivanka Toudjarska; Gang Wang; Silvio Wuschko; David Bumcrot; Victor Koteliansky; Stefan Limmer; Muthiah Manoharan; Hans-Peter Vornlocher
Journal:  Nature       Date:  2004-11-11       Impact factor: 49.962

9.  Activation of the interferon system by short-interfering RNAs.

Authors:  Carol A Sledz; Michelle Holko; Michael J de Veer; Robert H Silverman; Bryan R G Williams
Journal:  Nat Cell Biol       Date:  2003-08-24       Impact factor: 28.824

10.  Five- and six-membered conformationally locked 2',4'-carbocyclic ribo-thymidines: synthesis, structure, and biochemical studies.

Authors:  Puneet Srivastava; Jharna Barman; Wimal Pathmasiri; Oleksandr Plashkevych; Małgorzata Wenska; Jyoti Chattopadhyaya
Journal:  J Am Chem Soc       Date:  2007-06-07       Impact factor: 15.419

View more
  110 in total

Review 1.  RNA interference trigger variants: getting the most out of RNA for RNA interference-based therapeutics.

Authors:  Nicholas M Snead; John J Rossi
Journal:  Nucleic Acid Ther       Date:  2012-06       Impact factor: 5.486

2.  Cell biology forum: Genome-wide view of mitosis.

Authors:  Jason R Swedlow; Cecilia Cotta-Ramusino; Stephen J Elledge
Journal:  Nature       Date:  2010-04-01       Impact factor: 49.962

3.  Minor-groove-modulating adenosine replacements control protein binding and RNAi activity in siRNAs.

Authors:  Hayden Peacock; Erik Fostvedt; Peter A Beal
Journal:  ACS Chem Biol       Date:  2010-10-07       Impact factor: 5.100

Review 4.  DNA nanotechnology from the test tube to the cell.

Authors:  Yuan-Jyue Chen; Benjamin Groves; Richard A Muscat; Georg Seelig
Journal:  Nat Nanotechnol       Date:  2015-09       Impact factor: 39.213

5.  Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin.

Authors:  Shanthi Ganesh; Martin L Koser; Wendy A Cyr; Girish R Chopda; Junyan Tao; Xue Shui; Bo Ying; Dongyu Chen; Purva Pandya; Edmond Chipumuro; Zakir Siddiquee; Kevin Craig; Chengjung Lai; Henryk Dudek; Satdarshan P Monga; Weimin Wang; Bob D Brown; Marc T Abrams
Journal:  Mol Cancer Ther       Date:  2016-07-07       Impact factor: 6.261

Review 6.  Silencing disease genes in the laboratory and the clinic.

Authors:  Jonathan K Watts; David R Corey
Journal:  J Pathol       Date:  2011-11-09       Impact factor: 7.996

Review 7.  Advances in Biomaterials for Drug Delivery.

Authors:  Owen S Fenton; Katy N Olafson; Padmini S Pillai; Michael J Mitchell; Robert Langer
Journal:  Adv Mater       Date:  2018-05-07       Impact factor: 30.849

Review 8.  Nanomedicines based on recombinant fusion proteins for targeting therapeutic siRNA oligonucleotides.

Authors:  Johannes Winkler
Journal:  Ther Deliv       Date:  2011-07

Review 9.  RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials.

Authors:  Eunice L Lozada-Delgado; Nilmary Grafals-Ruiz; Pablo E Vivas-Mejía
Journal:  Life Sci       Date:  2017-08-31       Impact factor: 5.037

10.  Hydrogel-nanoparticle composites for optically modulated cancer therapeutic delivery.

Authors:  Laura E Strong; Shreyas N Dahotre; Jennifer L West
Journal:  J Control Release       Date:  2014-01-23       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.